Krystal Biotech Inc

+0.82 (+1.04%)
4:59:06 PM EDT: $80.00 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.06B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.17 Million
Adjusted EPS-$1.44
See more estimates
10-Day MA$77.76
50-Day MA$78.39
200-Day MA$74.14
See more pivots

Krystal Biotech Inc Stock, NASDAQ:KRYS

2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania 15203
United States of America
Phone: +1.412.586.5830
Number of Employees: 210


Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It is also involved in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.